Webinar description

TheraPsil is disrupting traditional psychedelic clinical trial models with stakeholder-funded research. TheraPsil recently launched a clinical trial in Canada exploring how psilocybin-assisted psychotherapy can improve overall wellbeing. This initiative is unique for several reasons. In part because it does not target a particular disease state. Also, unlike typical industry-sponsored trials, this trial is “stakeholder-funded”, meaning that participants must pay to participate. Learn more about this innovative trial, the motivations behind it, and the scientific and ethical considerations that it evokes.

    1. Stakeholder-Funded Model for Psychedelics Clinical Trials

About this webinar

  • $10.00
  • 1 hour of video content

Panelists

  • Kamaya Lawrence, Clinical Research Manager TheraPsil

  • Spencer Hawkswell, President and CEO TheraPsil

  • Sonia Brodie (co-host), Clinical Trial Professional, Board Member MAPS Canada

  • Rielle Capler (co-host), MHA, PhD, Executive Director MAPS Canada

Learning Objectives

  • Describe the goals and design of Therapsil’s new psilocybin-assisted psychotherapy clinical trial.

  • Differentiate stakeholder-funded clinical research from traditional industry-sponsored trials.

  • Assess the potential benefits and challenges associated with stakeholder-funded models in psychedelic research.

  • Identify key scientific considerations, including study methodology, safety protocols, and outcome measures.

  • Discuss the ethical questions raised by charging participants to join a clinical trial.

  • Understand the motivations behind launching a wellbeing-focused psychedelic trial at this time.

  • Evaluate how this model could shape the future of psychedelic research and access pathways in Canada.

Start your learning journey

Enroll today

Categories